Choose Your Location
|
![]() |
Brisbane, Calif. (Map) -
PARP is a novel, validated target for cancer treatment. PARP1 plays a central role in cell proliferation and in DNA repair. BiPar scientists will present results showing that PARP1 gene expression is significantly upregulated in many but not all tumor types. BiPar's novel, proprietary PARP inhibitors are members of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit tumor cell proliferation and are active against a broad range of tumor types. BiPar is initiating Phase 1b and Phase 2 clinical trials of BSI-201, its lead PARP inhibitor, in several major cancers. That research program has been directed in large part by the molecular biomarker data being presented at these meetings.
"These findings will focus our efforts on those tumor types with the
greatest opportunity for clinical success," said
The schedule of presentations is as follows: Title: The novel PARP-1 inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotopic activity in human pancreatic cancer When: Wednesday, Oct. 24, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Davide Melisi, M.D., Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center Title: PARP-1 gene over-expression in primary human cancers: A potential marker for PARP inhibition. When: Thursday, Oct. 25, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar Title: The PARP1 gene is over-expressed in triple negative breast cancer When: Thursday, Nov. 15, 6 to 8 p.m. CEST Where: EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer," Sheraton Brussels, Hotel & Towers, Brussels, Belgium Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar
About BiPar Sciences
BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
|
|


